epiderstatin: structure given in first source; isolated from Streptomyces pulveraceus subsp. epiderstagenes; inhibits mitogenic activity of epidermal growth factor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6438515 |
| MeSH ID | M0171469 |
| Synonym |
|---|
| epiderstatin |
| 4-[(3z)-3-[(3s,5s)-3,5-dimethyl-6-oxopiperidin-2-ylidene]-2-oxopropyl]piperidine-2,6-dione |
| 2,6-piperidinedione, 4-(3-(3,5-dimethyl-6-oxo-2-piperidinylidene)-2-oxopropyl)-, (3s-(2z,3alpha,5beta))- |
| 4-(3-(3,5-dimethyl-2-oxopiperidin-6-ylidene)-2-oxopropyl)-2,6-piperidinedione |
| 126602-16-2 |
Epiderstatin is a unique glutarimide antibiotic. It was found by screening for inhibitors of the signal transduction of epidermal growth factor (EGF)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Epiderstatin is a unique glutarimide antibiotic which was found by screening for inhibitors of the signal transduction of epidermal growth factor (EGF). " | ( Epiderstatin induces the flat reversion of NRK cells transformed by temperature-sensitive Rous sarcoma virus. Isono, K; Osada, H; Sasaki, M; Sonoda, T, 1992) | 3.17 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Epiderstatin did not inhibit the protein kinase activity of p60v-src." | ( Epiderstatin induces the flat reversion of NRK cells transformed by temperature-sensitive Rous sarcoma virus. Isono, K; Osada, H; Sasaki, M; Sonoda, T, 1992) | 2.45 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.61) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||